Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 87 versus FENTANYL CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 87 versus FENTANYL CITRATE.
FENTANYL-87 vs FENTANYL CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid that primarily acts as a mu-opioid receptor agonist, inhibiting adenylate cyclase, decreasing cAMP production, and modulating ion channels (calcium, potassium) to reduce neurotransmitter release and neuronal excitability.
Fentanyl is a potent synthetic opioid agonist that primarily acts on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and euphoria. It also interacts with kappa and delta opioid receptors to a lesser extent. By binding to these receptors, fentanyl inhibits adenylate cyclase, reduces cAMP production, closes voltage-gated calcium channels, and opens inwardly rectifying potassium channels, resulting in hyperpolarization and reduced neurotransmitter release.
IV: 0.5-2 mcg/kg as a bolus; continuous infusion: 0.7-10 mcg/kg/hr. Transdermal: 25-100 mcg/h every 72 hours. Transmucosal (buccal or lozenge): 200-1600 mcg as a single dose.
Initial adult dose 50-100 mcg IV/IM every 1-2 hours as needed for pain; for anesthesia induction 2-20 mcg/kg IV.
None Documented
None Documented
Terminal elimination half-life is approximately 3–12 hours (mean 7 hours) in adults; prolonged to up to 20–30 hours in elderly, critically ill, or patients with hepatic impairment. Context-sensitive half-life increases with infusion duration.
Terminal elimination half-life: 3-12 hours (mean 4-6 hours in adults). Context: Prolonged with hepatic impairment, elderly, or continuous infusion (context-sensitive half-life increases with infusion duration).
Primarily hepatic metabolism (>90%) to norfentanyl and other inactive metabolites; renal excretion of metabolites accounts for approximately 75% of total elimination, with about 9% excreted unchanged in urine. Fecal excretion is minimal (<9%).
Primarily hepatic metabolism (N-dealkylation to norfentanyl and other metabolites); less than 10% excreted unchanged in urine; approximately 9% excreted in feces via biliary elimination.
Category D/X
Category D/X
Opioid Agonist
Opioid Agonist